Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection.

ABSTRACT: Sodium glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RA) were initially approved to improve glycemic control in the treatment of type 2 diabetes. Clinical trials have also demonstrated beneficial effects with regards to cardiovascular and renal parameters. Beyond improving glycemic control, these therapies promote weight loss and lower blood pressure when used individually, and in an additive manner when used together. Accordingly, taking advantage of complementary mechanisms of action with the combined use of these two classes of agents to further improve cardiorenal outcomes is conceptually appealing, but has yet to be explored in detail in clinical trials. In this review, we discuss proposed mechanisms for renal protection, clinical benef

SUBMITTER: Sridhar VS 

PROVIDER: S-EPMC7860654 | biostudies-literature | 2020 Oct-Dec

REPOSITORIES: biostudies-literature